Lobe Sciences Ltd.
LOBE
CNSX
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -69.57% | 100.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.94% | 80.00% | |||
| Operating Income | 22.94% | -80.00% | |||
| Income Before Tax | 42.28% | -100.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.28% | -100.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 35.03% | 93.18% | |||
| Net Income | 53.59% | -101.97% | |||
| EBIT | 22.94% | -80.00% | |||
| EBITDA | -- | -81.59% | |||
| EPS Basic | 99.65% | -19,791.67% | |||
| Normalized Basic EPS | 99.76% | -21,614.29% | |||
| EPS Diluted | 99.65% | -19,791.67% | |||
| Normalized Diluted EPS | 99.76% | -21,614.29% | |||
| Average Basic Shares Outstanding | 13,431.82% | -98.98% | |||
| Average Diluted Shares Outstanding | 13,431.82% | -98.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||